

Title (en)  
SPECIFIC HUMAN ANTIBODIES

Title (de)  
SPEZIFISCHE HUMANE ANTIKÖRPER

Title (fr)  
ANTICORPS HUMAINS SPECIFIQUES

Publication  
**EP 1646401 A2 20060419 (EN)**

Application  
**EP 04777349 A 20040630**

Priority  
• US 2004021099 W 20040630  
• US 61084003 A 20030630

Abstract (en)  
[origin: WO2005005455A2] The present invention provides antibodies that bind an epitope of PSGL-1 comprising the motif D-X-Y-D, wherein X represents any amino acid or the covalent linkage between D and Y, and Y is sulfated, which antibody can be complexed with one or more copies of an agent. The antibodies of the invention can be used in a method of inducing antibody-dependent cell cytotoxicity and/or stimulating natural killer (NK) cells or T cells. In addition, by administering these antibodies to a patient in need thereof, a method of inducing cell death is provided. A method of preventing infection by a virus (e.g., HIV) by administering to a patient in need thereof an antibody of the present invention is also provided. The present invention also provides a method of introducing an agent into a cell that expresses sulfated PSGL-1 by coupling or complexing an agent to an antibody of the present invention and administering the complex to the cell. Finally, the present invention provides methods of diagnosis, prognosis and staging using the present antibodies.

IPC 1-7  
**A61K 39/395**

IPC 8 full level  
**A61K 39/395** (2006.01); **A61K 47/48** (2006.01); **A61P 35/00** (2006.01); **C07K 16/06** (2006.01); **C07K 16/28** (2006.01); **C07K 16/36** (2006.01); **C07K 16/44** (2006.01); **C12N 5/07** (2010.01); **C12N 5/0783** (2010.01); **C12N 5/09** (2010.01); **G01N 33/574** (2006.01); **A61P 31/18** (2006.01)

CPC (source: EP KR)  
**A61K 31/65** (2013.01 - KR); **A61K 47/6809** (2017.07 - EP); **A61K 47/6849** (2017.07 - EP); **A61P 7/02** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 31/18** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **A61P 35/04** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 16/06** (2013.01 - KR); **C07K 16/28** (2013.01 - KR); **C07K 16/2896** (2013.01 - EP); **C07K 16/36** (2013.01 - EP); **C07K 16/44** (2013.01 - EP); **C07K 2317/34** (2013.01 - EP); **C07K 2317/52** (2013.01 - EP); **C07K 2317/622** (2013.01 - EP); **C07K 2317/732** (2013.01 - EP); **C07K 2317/734** (2013.01 - EP); **C07K 2317/77** (2013.01 - EP); **C07K 2319/00** (2013.01 - EP)

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)  
**WO 2005005455 A2 20050120**; **WO 2005005455 A3 20060216**; AU 2004256113 A1 20050120; BR PI0411944 A 20070102; CA 2531283 A1 20050120; CN 1897970 A 20070117; EP 1646401 A2 20060419; EP 1646401 A4 20070718; IL 172511 A0 20060410; JP 2007527393 A 20070927; KR 20060107501 A 20061013; MX PA06000253 A 20070308; RU 2006102571 A 20070820

DOCDB simple family (application)  
**US 2004021099 W 20040630**; AU 2004256113 A 20040630; BR PI0411944 A 20040630; CA 2531283 A 20040630; CN 200480024911 A 20040630; EP 04777349 A 20040630; IL 17251105 A 20051212; JP 2006518747 A 20040630; KR 20067000219 A 20051230; MX PA06000253 A 20040630; RU 2006102571 A 20040630